Lung Cancer |
|
|
Clinical Trial: National Lung Screening Trial (NLST)
This study is no longer recruiting patients.
Purpose
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for lung cancer. It is not yet known whether helical CT scan is more effective than chest x-ray in reducing death from lung cancer.
PURPOSE: Randomized clinical trial to compare the effectiveness of helical CT scan with that of chest x-ray in screening individuals who are at high risk for developing lung cancer.
| Condition | Treatment or Intervention |
|---|---|
| Small Cell Lung Cancer Non-small cell lung cancer | Procedure: bronchoscopic and lung imaging studies Procedure: comparison of screening methods Procedure: screening intervention |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Lung Cancer
Study Type: Observational
Study Design: Screening
OBJECTIVES:
- Compare whether screening with low-dose helical CT scan vs chest x-ray reduces lung cancer-specific mortality in participants who are at high risk for developing lung cancer.
OUTLINE: This is a randomized, multicenter study. Participants are randomized to 1 of 2 screening arms.
- Arm I: Participants undergo helical CT scan.
- Arm II: Participants undergo chest x-ray. Participants in both arms undergo screening initially and then annually for 2 years.
Participants will then be contacted annually by mail or telephone for several years.
The National Lung Screening Trial (NLST) represents the union of two NCI-sponsored activities, the NCI Lung Screening Study I and the American College of Radiology Imaging Network (ACRIN). For more information, please access the ACRIN trial on Cancer.gov. The protocol ID is ACRIN-6654.
PROJECTED ACCRUAL: A total of 50,000 participants will be accrued for this study within 2 years.
Eligibility
Ages Eligible for Study: 55 Years - 74 Years, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Heavy smoker or former smoker (quit within last 15 years)
- No prior cancer (other than nonmelanoma skin cancer or in situ cancer) within past 5 years
PATIENT CHARACTERISTICS: Age
- 55 to 74
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
PRIOR CONCURRENT THERAPY: Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Location Information
Alabama
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35233, United States
California
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States
Colorado
University of Colorado Cancer Center at University of Colorado Health Sciences Center, Denver, Colorado, 80262, United States
District of Columbia
Georgetown University Medical Center, Washington, District of Columbia, 20007, United States
Florida
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612-9497, United States
Mayo Clinic, Jacksonville, Florida, 32224, United States
Georgia
Emory University School of Medicine, Atlanta, Georgia, 30322, United States
Hawaii
Pacific Health Research Institute, Honolulu, Hawaii, 96813, United States
Idaho
Mountain States Tumor Institute - Boise, Boise, Idaho, 83712, United States
Illinois
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, 60611, United States
Iowa
University of Iowa, Iowa City, Iowa, 52242-1011, United States
Kentucky
Jewish Heart and Lung Institute, Louisville, Kentucky, 40202, United States
Jewish Hospital, Louisville, Kentucky, 40202-1886, United States
Louisiana
Alton Ochsner Medical Foundation Hospital, New Orleans, Louisiana, 70121, United States
Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States
Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231, United States
Massachusetts
Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States
Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States
Michigan
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, 48202, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-0942, United States
Minnesota
Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States
University of Minnesota Cancer Center, Minneapolis, Minnesota, 55455, United States
Missouri
Mallinckrodt Institute of Radiology, St. Louis, Missouri, 63108, United States
New Hampshire
Norris Cotton Cancer Center at Dartmouth Medical School, Lebanon, New Hampshire, 03756-0002, United States
New Jersey
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, 08690, United States
North Carolina
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1082, United States
Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States
Ohio
St. Elizabeth Cancer Center at St. Elizabeth Health Center - Youngstown, Youngstown, Ohio, 44501, United States
Pennsylvania
Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, United States
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15236, United States
Rhode Island
Roger Williams Medical Center, Providence, Rhode Island, 02908-4735, United States
South Carolina
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, 29425, United States
Tennessee
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, 37232-6838, United States
Texas
University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States
Utah
Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States
Wisconsin
CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, 54449, United States
John K. Gohagan, PhD, FACE, Study Chair, National Cancer Institute (NCI)
Denise R. Aberle, MD, Principal Investigator, Jonsson Comprehensive Cancer Center
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: April 2004
Last Updated: October 13, 2004
Record first received: October 3, 2002
ClinicalTrials.gov Identifier: NCT00047385
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


